Organon & Co.
Organon & Co. (OGN) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
ogn · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Organon & Co. (OGN) measures how much investors pay for each dollar of the company's trailing earnings. OGN's current PE ratio of 14.16x is calculated by dividing its stock price of $13.38 by its TTM earnings per share of $0.94. +125.1% elevated vs 5Y avg 6.3x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2017 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 9 fiscal years · Front-end computedMinQ1 · 25%4.4x
MedianQ3 · 75%9.9x
Max
At 14.16x, OGN's current P/E is higher than in 100% of its annual fiscal year readings over the past 9 years — historically elevated.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Drug Manufacturers - General · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Organon & Co.You OGN | $3.5B | 14.16x | -41.7% | $0.94 |
 Alvotech ALVO | $1.2B | 51.30x | +111.1% | $0.10 |
 Aurinia Pharmaceuticals Inc. AUPH | $2.0B | 7.46x | -69.3% | $2.14 |
 Avadel Pharmaceuticals plc AVDL | $2.1B | N/A | — | -$0.51 |
 Guardian Pharmacy Services, Inc. GRDN | $2.6B | 38.14x | +57.0% | $0.79 |
 Harmony Biosciences Holdings, Inc. HRMY | $1.9B | 13.56x | -44.2% | $2.76 |
 Pediatrix Medical Group, Inc. MD | $1.8B | 11.03x | -54.6% | $1.94 |
Industry Average 5 peers with valid PE | — | 24.30x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | 9.95x | $0.72 | +124.2% | |
2024-12-31 FY2024 | 4.44x | $3.36 | +23.4% | |
2023-12-31 FY2023 | 3.60x | $4.01 | -53.5% | |
2022-12-31 FY2022 | 7.74x | $3.61 | +35.4% | |
2021-12-31 FY2021 | 5.71x | $5.33 | +46.4% | |
2020-12-31 FY2020 | 3.90x | $8.52 | +49.2% | |
2019-12-31 FY2019 | 2.62x | $12.71 | -33.1% | |
2018-12-31 FY2018 | 3.91x | $8.51 | -16.3% | |
2017-12-31 FY2017 | 4.67x | $7.11 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Organon & Co. (OGN) measures how much investors pay for each dollar of the company's trailing earnings. OGN's current PE ratio of 14.16x is calculated by dividing its stock price of $13.38 by its TTM earnings per share of $0.94.
Frequently asked questions
OGN pe ratio · 6 questionsOGN's current PE ratio is 14.16x as of 2026-06-08, based on a stock price of $13.38 and TTM EPS of $0.94. Data sourced from Financial Modeling Prep via OGN's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Organon & Co. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08